Abstract
recent studies have provided novel evidence regarding the effect of nicotine agonists on the prevention or modulation of cytokines storm and reduction of infection. In this study we tried to attempt to address these issues from a therapeutic perspective of nicotine agonists in this manner and we describe one of the most challenging theories of immunotherapy in coronavirus-19 (COVID-19). The analysis of the proposed mechanism goes beyond the physiological consequences of a way to design new strategies to provide anti-inflammatory drugs.
Keywords:
COVID-19; Immunotherapy; Nicotinic agonist.
Copyright © 2020 Elsevier Ltd. All rights reserved.
MeSH terms
-
Anti-Inflammatory Agents / administration & dosage*
-
Anti-Inflammatory Agents / therapeutic use
-
Betacoronavirus
-
Biomarkers / metabolism
-
COVID-19
-
Cholinergic Agents / therapeutic use
-
Coronavirus Infections / drug therapy*
-
Coronavirus Infections / immunology*
-
Coronavirus Infections / mortality
-
Cytokines / metabolism
-
Humans
-
Immune System / drug effects*
-
Immune System / virology*
-
Immunotherapy
-
Inflammation
-
Nicotine / metabolism
-
Nicotinic Agonists / administration & dosage*
-
Pandemics
-
Pneumonia, Viral / drug therapy*
-
Pneumonia, Viral / immunology*
-
Pneumonia, Viral / mortality
-
Receptors, Nicotinic / metabolism
-
SARS-CoV-2
-
Survivors
-
Treatment Outcome
Substances
-
Anti-Inflammatory Agents
-
Biomarkers
-
Cholinergic Agents
-
Cytokines
-
Nicotinic Agonists
-
Receptors, Nicotinic
-
Nicotine